In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business ...

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines. Valued ...

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for ...

Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic ...

The vaccine maker is expanding beyond its COVID-focused offerings.

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value ...

Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated ...

Investing.com -- Moderna (NASDAQ:MRNA) stock rose 10% on Thursday, extending its winning streak to a fourth consecutive session and reaching its highest intraday level since November 2024.